中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.029 seconds)

    PATHOLOGICALLY-ACTIVATED THERAPEUTICS
    14.
    发明申请
    PATHOLOGICALLY-ACTIVATED THERAPEUTICS 审中-公开
    病理性激活的治疗药物

    公开(公告)号：WO2011085213A2

    公开(公告)日：2011-07-14

    申请号：PCT/US2011/020536

    申请日：2011-01-07

    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE ,  LIPTON, Stuart, A.

    Inventor： LIPTON, Stuart, A.

    IPC: G01N33/53

    CPC classification number: G01N33/53

    Abstract: Disclosed are methods and compositions for identifying, producing, and using pathologically-activated targeting compounds. Pathologically- activated compounds are compound that only have an effect, or have a disproportionate effect, on a target molecule when a pathological condition exists.

    Abstract translation: 公开了鉴定，生产和使用病理活化的靶向化合​​物的方法和组合物。 病理活性化合物是当病理状态存在时仅对靶分子具有作用或具有不成比例效应的化合物。

    TREATMENT OF INSULIN RESISTANCE/METABOLIC SYNDROME TO ALLEVIATE THE RISKS OF DEMENTIA
    15.
    发明申请
    TREATMENT OF INSULIN RESISTANCE/METABOLIC SYNDROME TO ALLEVIATE THE RISKS OF DEMENTIA 审中-公开

    公开(公告)号：WO2005110468A3

    公开(公告)日：2005-11-24

    申请号：PCT/US2005/016248

    申请日：2005-05-10

    Applicant: THE BURNHAM INSTITUTE ,  LIPTON, Stuart, A. ,  EINHORN, Daniel

    Inventor： LIPTON, Stuart, A. ,  EINHORN, Daniel

    IPC: C12Q1/00 ,  C12Q1/60 ,  G01N31/00

    Abstract: This invention relates to Applicant’s discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer’s disease. Applicant’s invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant’s invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with β-amyloid protein for the IDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.

    NEUROPROTECTIVE COMPOSITIONS AND METHODS
    17.
    发明申请
    NEUROPROTECTIVE COMPOSITIONS AND METHODS 审中-公开
    神经保护组合物和方法

    公开(公告)号：WO2008108825A3

    公开(公告)日：2008-12-18

    申请号：PCT/US2007021748

    申请日：2007-10-10

    Applicant: BURNHAM INST MEDICAL RESEARCH ,  LIPTON STUART A ,  SATOH TAKUMI

    Inventor： LIPTON STUART A ,  SATOH TAKUMI

    IPC: A01N33/02 ,  A61K31/13

    CPC classification number: C07C62/32 ,  C07C62/38 ,  C07C69/757 ,  C07C2602/26

    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keapl, a negative regulator of the transcription factor Nrf2, and prevent Keapl -mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keapl /Nrf2 complex.

    Abstract translation: 神经突起伸展促进前列腺素（NEPPs）和其它电子化合物结合Keapl，转录因子Nrf2的负调节物，并防止Keapl介导的Nrf2的失活，因此，提高Nrf2的易位到神经元细胞的细胞核中。 因此，提供了神经保护组合物和相关方法，其使用这样的神经保护性化合物以及这些化合物的前体药物来引起Nrf2从Keap1 / Nrf2复合体解离。

    NEUROPROTECTIVE SYNERGY OF ERYTHROPOIETIN AND INSULIN-LIKE GROWTH FACTOR
    19.
    发明申请
    NEUROPROTECTIVE SYNERGY OF ERYTHROPOIETIN AND INSULIN-LIKE GROWTH FACTOR 审中-公开

    公开(公告)号：WO2003103608A3

    公开(公告)日：2003-12-18

    申请号：PCT/US2003/018645

    申请日：2003-06-11

    Applicant: THE BURNHAM INSTITUTE ,  DIGICAYLIOGLU, Murat ,  LIPTON, Stuart, A.

    Inventor： DIGICAYLIOGLU, Murat ,  LIPTON, Stuart, A.

    IPC: G01N33/53

    Abstract: The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuropotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a does of at most 200 U/kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathicpain, migraine, glaucoma, drug addition, drug withdrawal, drug dependency, depression or anxiety.

    NEUROPROTECTIVE SYNERGY OF ERYTHROPOIETIN AND INSULIN-LIKE GROWTH FACTOR
    20.
    发明申请
    NEUROPROTECTIVE SYNERGY OF ERYTHROPOIETIN AND INSULIN-LIKE GROWTH FACTOR 审中-公开
    红细胞生成素和胰岛素样生长因子的神经保护性协同

    公开(公告)号：WO2003103608A2

    公开(公告)日：2003-12-18

    申请号：PCT/US2003/018645

    申请日：2003-06-11

    Applicant: THE BURNHAM INSTITUTE ,  DIGICAYLIOGLU, Murat ,  LIPTON, Stuart, A.

    Inventor： DIGICAYLIOGLU, Murat ,  LIPTON, Stuart, A.

    IPC: A61K

    CPC classification number: A61K38/30 ,  A61K2300/00

    Abstract: The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuropotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a does of at most 200 U/kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathicpain, migraine, glaucoma, drug addition, drug withdrawal, drug dependency, depression or anxiety.

    Abstract translation: 本发明提供了一种通过在兴奋性侮辱时或之后诱导神经元细胞中促红细胞生成素（EPO）信号通路来提供急性神经保护作用的方法; 并在兴奋性侮辱时间附近或之后在神经元细胞中诱导胰岛素样生长因子（IGF）信号通路，从而在神经元细胞中产生协同的急性神经保护作用。 本发明还提供了一种通过以至多200U / kg的剂量给予受试者EPO或其活性片段或类似物来预防或降低受试者神经系统病症的严重性的方法; 并向受试者施用IGF或其活性片段或类似物，由此提供神经病症。 这种方法可用于预防或减轻例如阿尔茨海默氏病，帕金森病，亨廷顿病，癫痫，肌萎缩性侧索硬化，多发性硬化，运动障碍，HIV相关性痴呆，HIV相关神经病，神经病理性疼痛 ，偏头痛，青光眼，药物添加，戒毒，药物依赖，抑郁或焦虑。

Patent Agency Ranking